Bicycle Therapeutics (BCYC) Competitors $7.81 -0.07 (-0.89%) Closing price 04:00 PM EasternExtended Trading$7.61 -0.20 (-2.56%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. IDYA, DNLI, BHC, TVTX, ETNB, SRPT, OCUL, DYN, ANIP, and VERAShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include IDEAYA Biosciences (IDYA), Denali Therapeutics (DNLI), Bausch Health Cos (BHC), Travere Therapeutics (TVTX), 89BIO (ETNB), Sarepta Therapeutics (SRPT), Ocular Therapeutix (OCUL), Dyne Therapeutics (DYN), ANI Pharmaceuticals (ANIP), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors IDEAYA Biosciences Denali Therapeutics Bausch Health Cos Travere Therapeutics 89BIO Sarepta Therapeutics Ocular Therapeutix Dyne Therapeutics ANI Pharmaceuticals Vera Therapeutics Bicycle Therapeutics (NASDAQ:BCYC) and IDEAYA Biosciences (NASDAQ:IDYA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Is BCYC or IDYA more profitable? IDEAYA Biosciences has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -1,257.00%. IDEAYA Biosciences' return on equity of -31.42% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicycle Therapeutics-1,257.00% -32.43% -26.80% IDEAYA Biosciences N/A -31.42%-29.45% Which has more volatility and risk, BCYC or IDYA? Bicycle Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500. Do insiders and institutionals have more ownership in BCYC or IDYA? 86.2% of Bicycle Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 22.9% of Bicycle Therapeutics shares are owned by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings and valuation, BCYC or IDYA? Bicycle Therapeutics has higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicycle Therapeutics$35.28M15.34-$169.03M-$3.51-2.23IDEAYA Biosciences$7M355.82-$274.48M-$3.79-7.50 Does the media favor BCYC or IDYA? In the previous week, IDEAYA Biosciences had 19 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 21 mentions for IDEAYA Biosciences and 2 mentions for Bicycle Therapeutics. Bicycle Therapeutics' average media sentiment score of 0.55 beat IDEAYA Biosciences' score of 0.42 indicating that Bicycle Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend BCYC or IDYA? Bicycle Therapeutics presently has a consensus price target of $22.22, suggesting a potential upside of 184.54%. IDEAYA Biosciences has a consensus price target of $44.50, suggesting a potential upside of 56.58%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than IDEAYA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicycle Therapeutics 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.74 SummaryBicycle Therapeutics beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$546.14M$3.44B$6.19B$10.60BDividend YieldN/A2.26%5.72%4.86%P/E Ratio-2.2323.2429.6428.46Price / Sales15.34477.59577.46128.87Price / CashN/A44.5736.5560.64Price / Book0.6810.3512.076.53Net Income-$169.03M-$52.53M$3.32B$276.75M7 Day Performance-9.71%-0.22%-0.16%0.20%1 Month Performance10.16%10.89%5.76%1.67%1 Year Performance-69.15%14.19%65.71%32.73% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.4867 of 5 stars$7.81-0.9%$22.22+184.5%-69.9%$546.14M$35.28M-2.23240Upcoming EarningsIDYAIDEAYA Biosciences4.2953 of 5 stars$26.77+2.0%$43.36+62.0%-5.2%$2.30B$7M-7.0680News CoverageAnalyst ForecastAnalyst RevisionDNLIDenali Therapeutics4.137 of 5 stars$14.98-2.5%$33.50+123.6%-39.3%$2.25B$330.53M-5.35430BHCBausch Health Cos4.7105 of 5 stars$6.15+1.6%$9.00+46.5%-23.0%$2.24B$9.63B23.6420,700News CoveragePositive NewsUpcoming EarningsTVTXTravere Therapeutics2.9624 of 5 stars$26.20+4.1%$35.21+34.4%+52.9%$2.24B$233.18M-12.84460News CoverageUpcoming EarningsETNB89BIO2.8707 of 5 stars$14.80flat$25.81+74.4%+82.3%$2.19BN/A-4.1040Analyst DowngradeShort Interest ↓SRPTSarepta Therapeutics4.6 of 5 stars$21.96-0.7%$34.42+56.7%-82.5%$2.16B$1.90B-25.241,372Analyst ForecastOCULOcular Therapeutix4.289 of 5 stars$11.85+0.6%$22.63+90.9%+0.4%$2.05B$63.72M-9.26230Analyst RevisionDYNDyne Therapeutics3.0182 of 5 stars$14.03-0.1%$34.07+142.8%-51.0%$2.00BN/A-3.63100Positive NewsANIPANI Pharmaceuticals4.1315 of 5 stars$88.61-1.3%$99.14+11.9%+56.1%$1.95B$614.38M-115.08600VERAVera Therapeutics2.8976 of 5 stars$30.49+1.3%$63.00+106.6%-26.5%$1.92BN/A-8.5240News Coverage Related Companies and Tools Related Companies IDEAYA Biosciences Competitors Denali Therapeutics Competitors Bausch Health Cos Competitors Travere Therapeutics Competitors 89BIO Competitors Sarepta Therapeutics Competitors Ocular Therapeutix Competitors Dyne Therapeutics Competitors ANI Pharmaceuticals Competitors Vera Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts